USFDA gives tentative nod to Lupin for generic Brexpiprazole tablets

The product is a generic version of Otsuka Pharmaceutical’s Rexulti tablets in the same strengths, it added.

63
Medicine Tablet
Picture: Pixabay

Last Updated on October 9, 2021 by The Health Master

Lupin yesterday said it has received tentative nod from the US health regulator to market generic Brexpiprazole tablets, which are used with anti-depressant medicines for the treatment of major depressive disorder, in the American market.

The company has received tentative approval from the US Food and Drug Administration (USFDA) to market generic Brexpiprazole tablets in the strengths of 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg, Lupin said in a regulatory filing.

The product is a generic version of Otsuka Pharmaceutical’s Rexulti tablets in the same strengths, it added.

These tablets will be manufactured at the company’s Pithampur facility, Lupin said.

Brexpiprazole tablets are indicated for use as an adjunctive therapy to anti-depressants for the treatment of major depressive disorder (MDD) and for treatment of schizophrenia.

Zydus Cadila gets USFDA nod for drug to treat Psoriasis

Zydus Cadila gets USFDA nod for Antidepressant drug

Zydus Cadila gets tentative nod from USFDA for Brexpiprazole tablets

USFDA to review use of Blood Disorder Therapy in children

Aleor gets USFDA final approval for Metronidazole gel

Dr Reddy’s Labs gets USFDA nod for generic Librax capsules

NMC releases draft Post Graduate Medical Education Regulation 2021

FDA to launch prosecution against 77 Medical Stores

New Drugs, Cosmetics & Medical Devices bill should align with MDR…

Govt notifies amended Rules on Mfg of Ayurveda, Siddha and Unani…

NPPA releases draft of ceiling price calculation sheet for 2 drugs

CDSCO to start BA/BE studies registration process online from Oct 15

Latest Notifications regarding Pharmaceuticals

Telegram
WhatsApp
Facebook
LinkedIn
Google-news

Enter your email address:

Delivered by FeedBurner